



London, UK, 9 December 2013

Edison grows its international biopharmaceutical presence with initiation of coverage of BioLineRx

Edison Investment Research, a leading international investment research firm, announces the initiation of coverage of BioLineRx a dual US/Israel-listed biopharmaceutical company focused on the development of biomedical IP principally derived from academic sources in Israel.

Edison's report, *Exploiting IP from the land of milk and honey*, examines the catalyst-rich phase BioLineRx is about to enter over the next 12 months, which is expected to produce early clinical data from studies of two internal research and development projects, BL-8040 (acute myeloid leukaemia) and BL-8020 (HCV).

The report discusses the main stock catalyst, data from its lead partnered programme of a pivotal study of BL-1040 for the prevention of cardiac remodelling following acute myocardial infarction and from BL-5010 for benign skin lesions, expected in 2014. Ahead of these key catalysts, our healthcare team values the company at \$210m, equivalent to \$8.9/ADR (basic) or \$7.9/ADR (fully diluted).

For the full report see: www.edisoninvestmentresearch.com/research/company/biolinerx

About Edison Investment Research

The launch of coverage on BioLineRx is part of a programme of research initiations on biopharmaceutical companies exposed to global market opportunities. Edison provides detailed research coverage on more than 150 pharmaceutical and healthcare companies in Europe, North America, Australia and New Zealand. Its team of over 100 analysts and investment professionals works with leading companies, fund managers and investment banks worldwide to support its capital markets activity. It provides services to more than 400 retained corporate and investor clients from offices in London, New York, Frankfurt, Sydney and Wellington. All reports Edison publishes are available to download free of charge from its website www.edisongroup.com.

Edison is authorised and regulated by the Financial Services Authority (www.fsa.gov.uk/register/firmBasicDetails.do?sid=181584). Edison is not an adviser or broker-dealer and does not provide investment advice. Edison's reports are not solicitations to buy or sell any securities.

For more information please contact:

Robin Davison	Edison Investment Research	+44 (0)20 3077 5737
Jason Zhang PhD	Edison Investment Research	+1 646 653 7027

healthcare@edisongroup.com

About BioLineRx

BioLineRx is an Israel-based biotech company focused on the in-licensing and early development of therapeutics. It has a pipeline with five clinical and 13 preclinical candidates for a variety of indications in CNS, oncology, infectious disease, cardiovascular and autoimmune disease.

Frankfurt +49 (0)69 78 8076 960
Schumannstrasse 34b
60325 Frankfurt
Germany

London +44 (0)20 3077 5700
280 High Holborn
London, WC1V 7EE
United Kingdom

New York +1 646 653 7026
245 Park Avenue, 39th Floor
10167, New York
US

Sydney +61 (0)2 9258 1162
Level 33, Australia Square
264 George St, Sydney
NSW 2000, Australia

Wellington +64 (0)4 8948 555
Level 15, 171 Featherston St
Wellington 6011
New Zealand